Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mahakool is a multi-ingredient topical ophthalmic formulation developed and marketed by Grevis Pharma. It is primarily used as a decongestant and lubricant to treat ocular redness and irritation. The formulation contains **naphazoline hydrochloride** (0.05%) and **phenylephrine hydrochloride**, both of which are small molecule alpha-adrenergic agonists that induce vasoconstriction of the conjunctival blood vessels to reduce redness. It also includes **chlorpheniramine maleate**, an antihistamine that provides relief from allergic symptoms, and **carboxymethylcellulose** (CMC), which serves as a lubricant for dry eye conditions. The addition of camphor and menthol provides a cooling sensation upon application. Mahakool is indicated for allergic conjunctivitis, conjunctival hyperemia, and general eye strain or burning sensations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mahakool.